RxNews® Newsletter: Pipeline - RxSolutions.com Rasilez® aliskerin – Novartis. Rasilez, which was originally developed with Speedel, will represent the first new treatment approach for people with high
The heart of the matter: Supercautious FDA delays Aliskerin Approval Dec 20, 2006 Novartis has just submitted additional animal data to FDA showing that Aliskerin may be associated with a small incidence of colonic or
Newly Approved Drug Therapies 943 : Tekturna aliskiren Jun 20, 2008 Final Report Submission: 05/09; Novartis has agreed to provide evidence that it is not likely to be clinically useful to give aliskiren in a
Tekturna aliskiren tablets - Novartis Pharmaceuticals Information on the Novartis prescription medicine Tekturna.
Novartis investigational renin inhibitor Aliskiren offers once Mar 11, 2005 Study also demonstrates a safety and tolerability profile for Aliskiren comparable to placebo - Data published in the March issue of the
Phase 2b/3 data promising with new renin inhibitor in hypertension Nov 21, 2008 Shannon reported that Novartis anticipates submission for FDA approval of aliskerin sometime in 2006. Blocking the RAS cascade
Apples for Health- New Paradigm For Blood Pressure May 26, 2006 "Aliskerin is the first oral direct renin inhibitor and has the senior medical director for the aliskerin project for Novartis,
Bioorganic & Medicinal Chemistry : Rational design of 6- 2,4 5 and 6 Research on these scaffolds reached an apex with the discovery and development of aliskerin by scientists at Novartis and Speedel.
ACP: ObserverWeekly - 13 March 2007 Mar 13, 2007 Aliskerin tablets, which are manufactured as Tekturna by Novartis Pharmaceuticals Corp., should be available in pharmacies by the end of
First-in-class diabetic drug to make market impact Other therapies being investigated include Novartis& 39; renin inhibitor Aliskerin, currently at the phase II stage of development. Aliskerin is an orally
Top 7 BioPharma & Pharma Innovations of 2007 - Seeking Alpha Dec 17, 2007 Aliskerin Tekturna/Rasilez, Novartis NVS . Aliskerin, the first approved renin inhibitor, is probably best known for the story of its
Analysis: New Paradigm for Blood Pressure? - Health - redOrbit Aliskerin is the first oral direct renin inhibitor and has the potential to for the aliskerin project for Novartis, told United Press International.
Journals on the Web Presentation: Tablets, 150 & 300 mg aliskerin base. Brand name: Tekturna® U.S.A. . Source: Novartis; codeveloped with Speedel.
Scottish Medicines Consortium Minutes of SMC Meeting - Tuesday 1 10.2 aliskerin Rasilez Novartis Pharmaceuticals UK Ltd No. 462/08 . 10.2.1 In the absence of a submission from the holder of the marketing authorisation,
